Healthcare stalwart Merck & Co., Inc. (MRK) continues to strive toward developing its pipeline through acquisitions. The company recently announced that it would acquire clinical-stage biopharmaceutical company Imago BioSciences, Inc. (IMGO) for an approximate total equity value of $1.35 billion. The transaction, expected to close in the first quarter of 2023, should broaden MRK’s hematology portfolio.
In September, MRK’s Animal Health segment announced that it had signed a definitive agreement to acquire Vence, an innovator in virtual fencing for rotational grazing and livestock management, to bolster this segment’s portfolio.
